As ovary tumors with elevated CCNE1 level often exhibit higher Cdk2 expression [5, 15] and most of CCNE1-associated tumor promoting effects require the participation of Cdk2 [16], we reasoned that targeting Cdk2 may be an attractive alternative given the current availability of small molecule Cdk2 inhibitors. The gene discussed is CCNE1; the disease is ovarian neoplasm.